AVPR2 and autosomal dominant polycystic kidney disease: Lixivaptan is a selective vasopressin V2 receptor antagonist that was initially developed for the treatment of hyponatremia (1) and is currently being repurposed for the treatment of autosomal-dominant polycystic kidney disease (ADPKD).